Table 1 Demographics of 92 patients with Candida auris
Category | Total n = 92 (100%) |
|---|---|
Male | 48 (52.2%) |
Age group | |
16–35 years | 20 (21.7%) |
36–55 years | 26 (28.3%) |
56–75 years | 30 (32.6%) |
76–96 years | 16 (17.4%) |
Location in hospital | |
ICU | 30 (32.6%) |
Special care | 30 (32.6%) |
Ward | 27 (29.3%) |
Outpatient | 5 (5.4%) |
Diabetes mellitus | 26 (28.3%) |
Malignancy | 17 (18.5%) |
Surgery | 53 (57.6%) |
Abdominal | 12 (13%) |
Cardiothoracic | 8 (8.7%) |
Neurosurgery | 14 (15.2%) |
ENT | 9 (9.8%) |
Orthopedics | 7 (7.6%) |
Others | 2 (2.17%) |
ICU stay in last 30 days | 41 (44.6%) |
Last ICU stay duration (weeks) ≤ 2 Weeks | 31 (75.6%) |
HDU stay in last 30 days | 62 (67.4%) |
Last HDU stay duration (weeks) | |
≤ 2 Weeks | 52 (56.5%) |
Indwelling lines | 81 (88.04%) |
Antibiotics in last 90 days | 88 (95.6%) |
Antifungals in last 90 days | 36 (39.1%) |
Fluconazole | 19 (20.7%) |
Voriconazole | 3 (3.3%) |
Amphotericin | 7 (7.6%) |
> 1 Antifungal | 7 (7.6%) |
Prior antifungal duration (weeks) | |
≤ 2 Weeks | 25 (27.2%) |
Isolation of multi-drug resistant bacteria | |
Prior toC.auris (≤ 90 days) | 48 (52.2%) |
Coinfection with C.auris | 29 (31.5%) |
Infected cases | 65 (70.7%) |
Candidemia | 38 (58.5%) |
Non-candidemia | 27 (41.5%) |
UTI | 19 |
Peritonitis | 3 |
Nosocomial ventriculitis | 1 |
Empyema | 1 |
Surgical Site Infection | 1 |
Otitis externa | 1 |
Keratitis | 1 |
Colonized cases | 27 (29.3%) |
Asymptomatic candiduria | 21 |
Central line tip | 4 |
Ear Swab | 1 |
Oral Swab | 1 |
Antifungal resistance (n = 63) | |
Fluconazole | 63 (100%) |
Voriconazole | 18 (28.57%) |
Amphotericin | 5 (7.93%) |
Mean hospital stay (days) | 30.73 |
Median hospital stay (days) | 25 (1–163) |
Mortality | 39 (42.4%) |
C auris death | 19 (48.7%) |
14-day mortality | 29 (31.5%) |
Mean days in which mortality occurred (days) | 12.41 |
Median days in which mortality occurred (days) | 7 (1–69) |
Clinical failure | 38 (41.3%) |
Microbiological failure (Candidemia) | 11 (40.74%) |